Jubilant Pharmova Limited

Equities

JUBLPHARMA

INE700A01033

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:47 2024-04-24 am EDT 5-day change 1st Jan Change
682.6 INR -0.31% Intraday chart for Jubilant Pharmova Limited +1.63% +25.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility MT
India's Jubilant Pharmova posts quarterly profit RE
Jubilant Pharmova Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jubilant Ingrevia Redeems INR1 Billion at Maturity Date MT
Jubilant Pharmova Unit Gets US FDA's Approval for Technetium Sulfur Colloid Injection MT
Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023 CI
Jubilant Pharmova Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Domino's India operator Jubilant beats Q2 profit estimates on cheaper launches RE
Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2023, Payable on or Before September 29, 2023 CI
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023 CI
Jubilant Pharmova's Consolidated Profit Plunges in Fiscal Q1 MT
Jubilant Pharmova Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Indian shares set for flat start ahead of key earnings RE
Jubilant Pharmova Names Managing Director MT
Late Rally Led by Consumer Goods, Financials Lifts Indian Equities to Close Higher MT
Jubilant Pharmova CFO Steps Down MT
Jubilant Pharmova Limited Announces Change in Directorate CI
Jubilant Pharmova Limited Announces CFO Changes CI
INDIA STOCKS-Indian shares rise to five-month high on improved global cues RE
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023 CI
Jubilant Pharmova Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Jubilant Pharmanova's Canadian Arm Gets CA$24 Million Loan for Capacity Expansion MT
Jubilant Pharmova Gets VAI from US FDA for API Manufacturing Facility in Karnataka, India MT
Jubilant Pharmova Limited Appoints Shirish G. Belapure as Additional Director (Non-Executive, Independent) CI
Transcript : Jubilant Pharmova Limited, Q3 2023 Earnings Call, Feb 03, 2023
Chart Jubilant Pharmova Limited
More charts
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
More about the company
  1. Stock Market
  2. Equities
  3. JUBLPHARMA Stock
  4. News Jubilant Pharmova Limited
  5. Jubilant Pharmova : Subsidiary to Invest $92 Million to Expand US Facility